David Hallas (CEO) and Chris Wilks (CFO) presented an overview of their Full-Year results for the period ended 31 March 2026. Highlights included a 10% increase in Group Revenue, and Gross Margins rising to 48.6% (FY 2025: 45.1%), driven by growth in higher-margin markets. The team discussed the launch of ECOVAXXIN MS in Europe, the cautious outlook for China and the R&D growth pipeline. They also provided a detailed financial and operational review and the outlook for ECO, while answering a range of questions submitted by viewers. The full video of the presentation has been divided into chapters, as follows: 00:00 Introduction and Overview 09:05 Financial Review 24:10 R&D Growth Engine 31:11 Summary & Outlook 32:44 Q&A
